Targovax: Oncolytic adenovirus armed w immune stimulating transgene targeting basket of I-O indications. Strong results from Part 1 (ONCOS-102/Keytruda combo) trial in anti-PD1 refractory melanoma: 33% ORR in 9 pts: 1 CR, 2 PRs; immune act. in all 9 pts. Upcoming milestones: randomized data, Ph 1b/2 (mesothelioma, n=31) w/chemo: Jan 2020; Ph 1, Part 2 data (melanoma comb w/Keytruda, n=21): 1H2020; updates from collab partners in peritoneal metastasis & prostate exp 2020
Based in...
Clinical Stage
Phase l or ll, Pre-Clinical Stage
Disease Space
Anti-infectives, Antivirals, Immuno-Oncology, Immunotherapy, Oncology
Europe, Public
Market Cap
Therapeutic Modalities
Platform Technology, Vaccine
Lilleakerveien 2 C
Oslo, NO-0283

Company Participants at Solebury Trout KOL Day

  • Torbjørn Furuseth, Chief Financial Officer

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Top 10 Holders of Targovax ASA

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
KLP Kapitalforvaltning AS 1.63 1,031,244 0.81 Stakes 2019-12-31
Nordea Investment Management AB (Norway) 1.31 830,000 0.65 Funds 2020-05-29
Storebrand Asset Management AS 0.47 295,000 0.23 Funds 2020-06-30
Handelsbanken Fonder AB 0.16 99,669 0.08 Funds 2020-06-30
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.